OA12354A - Tartrate salts of thiazolidinedione derivative. - Google Patents

Tartrate salts of thiazolidinedione derivative. Download PDF

Info

Publication number: OA12354A
Authority: OA; OAPI
Prior art keywords: tartrate; solvaté; accordance; compound according; methyl
Prior art date: 2000-08-04

Application number

OA1200300028A

Other languages

English (en)

Inventor

Andrew Simon Craig

Tim Chien Ting Ho

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-04

Filing date

2001-08-03

Publication date

2004-03-19

2001-08-03 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2004-03-19 Publication of OA12354A publication Critical patent/OA12354A/en

Links

150000003892 tartrate salts Chemical class 0.000 title description 3
150000001467 thiazolidinediones Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 34
229940095064 tartrate Drugs 0.000 claims abstract description 14
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims abstract description 13
238000004519 manufacturing process Methods 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 56
239000007787 solid Substances 0.000 claims description 13
238000001035 drying Methods 0.000 claims description 5
239000012943 hotmelt Substances 0.000 claims description 5
238000000634 powder X-ray diffraction Methods 0.000 claims description 5
238000001237 Raman spectrum Methods 0.000 claims description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
238000002329 infrared spectrum Methods 0.000 claims description 4
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 3
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000003801 milling Methods 0.000 claims description 3
238000001694 spray drying Methods 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
238000010128 melt processing Methods 0.000 claims description 2
239000007909 solid dosage form Substances 0.000 claims description 2
238000004659 sterilization and disinfection Methods 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
229940125898 compound 5 Drugs 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 2
239000012453 solvate Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 17
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 10
238000000034 method Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
-1 acétone Chemical class 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
238000010992 reflux Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229940048879 dl tartaric acid Drugs 0.000 description 5
239000000463 material Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000009938 salting Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
238000010268 HPLC based assay Methods 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000000945 filler Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000007810 chemical reaction solvent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960001367 tartaric acid Drugs 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
238000005079 FT-Raman Methods 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
229920004459 Kel-F® PCTFE Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101100366942 Mus musculus Ston1 gene Proteins 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical compound FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940095107 e.s.p. Drugs 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000000449 magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Cosmetics (AREA)

OA1200300028A 2000-08-04 2001-08-03 Tartrate salts of thiazolidinedione derivative. OA12354A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0019224.5A GB0019224D0 (en)	2000-08-04	2000-08-04	Novel pharmaceutical

Publications (1)

Publication Number	Publication Date
OA12354A true OA12354A (en)	2004-03-19

Family

ID=9897026

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300028A OA12354A (en)	2000-08-04	2001-08-03	Tartrate salts of thiazolidinedione derivative.

Country Status (36)

Country	Link
US (1)	US20040014790A1 (fr)
EP (1)	EP1305311B1 (fr)
JP (1)	JP2004505970A (fr)
KR (1)	KR100755174B1 (fr)
CN (1)	CN1455778A (fr)
AP (1)	AP1785A (fr)
AT (1)	ATE384059T1 (fr)
AU (1)	AU2001276506A1 (fr)
BG (1)	BG107604A (fr)
BR (1)	BR0112982A (fr)
CA (1)	CA2417827A1 (fr)
CY (1)	CY1107252T1 (fr)
CZ (1)	CZ2003313A3 (fr)
DE (1)	DE60132461T2 (fr)
DK (1)	DK1305311T3 (fr)
DZ (1)	DZ3418A1 (fr)
EA (1)	EA005408B1 (fr)
EC (1)	ECSP034467A (fr)
ES (1)	ES2296772T3 (fr)
GB (1)	GB0019224D0 (fr)
HR (1)	HRP20030068B1 (fr)
HU (1)	HUP0300778A3 (fr)
IL (2)	IL154275A0 (fr)
MA (1)	MA25832A1 (fr)
MX (1)	MXPA03001085A (fr)
NO (1)	NO324596B1 (fr)
NZ (1)	NZ524030A (fr)
OA (1)	OA12354A (fr)
PL (1)	PL360662A1 (fr)
PT (1)	PT1305311E (fr)
SI (1)	SI1305311T1 (fr)
SK (1)	SK1462003A3 (fr)
UA (1)	UA76720C2 (fr)
WO (1)	WO2002012232A1 (fr)
YU (1)	YU14603A (fr)
ZA (1)	ZA200300961B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE39384E1 (en)	1993-09-01	2006-11-07	Smithkline Beecham P.L.C.	Substituted thiazolidinedione derivatives
DE102005034406A1 (de) *	2005-07-22	2007-02-01	Ratiopharm Gmbh	Neue Salze von Rosiglitazon
US7435741B2 (en) *	2006-05-09	2008-10-14	Teva Pharmaceutical Industries, Ltd.	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP3367946B1 (fr)	2015-10-27	2020-07-08	Nanopass Technologies Ltd.	Dispositif à micro-aiguilles avec guide mécanique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds

2000
- 2000-08-04 GB GBGB0019224.5A patent/GB0019224D0/en not_active Ceased
2001
- 2001-03-08 UA UA2003020938A patent/UA76720C2/uk unknown
- 2001-08-03 SK SK146-2003A patent/SK1462003A3/sk unknown
- 2001-08-03 SI SI200130808T patent/SI1305311T1/sl unknown
- 2001-08-03 IL IL15427501A patent/IL154275A0/xx active IP Right Grant
- 2001-08-03 US US10/343,845 patent/US20040014790A1/en not_active Abandoned
- 2001-08-03 BR BR0112982-1A patent/BR0112982A/pt not_active IP Right Cessation
- 2001-08-03 KR KR1020037001604A patent/KR100755174B1/ko not_active Expired - Fee Related
- 2001-08-03 EA EA200300230A patent/EA005408B1/ru not_active IP Right Cessation
- 2001-08-03 AP APAP/P/2003/002736A patent/AP1785A/en active
- 2001-08-03 CA CA002417827A patent/CA2417827A1/fr not_active Abandoned
- 2001-08-03 PT PT01954159T patent/PT1305311E/pt unknown
- 2001-08-03 OA OA1200300028A patent/OA12354A/en unknown
- 2001-08-03 WO PCT/GB2001/003511 patent/WO2002012232A1/fr not_active Ceased
- 2001-08-03 HR HR20030068A patent/HRP20030068B1/xx not_active IP Right Cessation
- 2001-08-03 ES ES01954159T patent/ES2296772T3/es not_active Expired - Lifetime
- 2001-08-03 AT AT01954159T patent/ATE384059T1/de not_active IP Right Cessation
- 2001-08-03 PL PL36066201A patent/PL360662A1/xx not_active Application Discontinuation
- 2001-08-03 DK DK01954159T patent/DK1305311T3/da active
- 2001-08-03 MX MXPA03001085A patent/MXPA03001085A/es active IP Right Grant
- 2001-08-03 AU AU2001276506A patent/AU2001276506A1/en not_active Abandoned
- 2001-08-03 NZ NZ524030A patent/NZ524030A/en unknown
- 2001-08-03 CN CN01815600A patent/CN1455778A/zh active Pending
- 2001-08-03 HU HU0300778A patent/HUP0300778A3/hu unknown
- 2001-08-03 DE DE60132461T patent/DE60132461T2/de not_active Expired - Fee Related
- 2001-08-03 YU YU14603A patent/YU14603A/sh unknown
- 2001-08-03 CZ CZ2003313A patent/CZ2003313A3/cs unknown
- 2001-08-03 JP JP2002518207A patent/JP2004505970A/ja not_active Withdrawn
- 2001-08-03 EP EP01954159A patent/EP1305311B1/fr not_active Expired - Lifetime
- 2001-08-03 DZ DZ013418A patent/DZ3418A1/fr active
2003
- 2003-02-03 NO NO20030530A patent/NO324596B1/no not_active IP Right Cessation
- 2003-02-03 IL IL154275A patent/IL154275A/en not_active IP Right Cessation
- 2003-02-03 MA MA27024A patent/MA25832A1/fr unknown
- 2003-02-04 ZA ZA200300961A patent/ZA200300961B/en unknown
- 2003-02-04 EC EC2003004467A patent/ECSP034467A/es unknown
- 2003-02-28 BG BG107604A patent/BG107604A/bg unknown
2008
- 2008-03-19 CY CY20081100309T patent/CY1107252T1/el unknown

Also Published As

Publication number	Publication date
EA005408B1 (ru)	2005-02-24
ES2296772T3 (es)	2008-05-01
KR100755174B1 (ko)	2007-09-03
NZ524030A (en)	2004-07-30
EP1305311A1 (fr)	2003-05-02
CZ2003313A3 (cs)	2004-02-18
HRP20030068A2 (en)	2005-02-28
US20040014790A1 (en)	2004-01-22
YU14603A (sh)	2006-05-25
DZ3418A1 (fr)	2002-02-14
NO20030530L (no)	2003-02-03
MXPA03001085A (es)	2003-05-27
NO20030530D0 (no)	2003-02-03
HUP0300778A3 (en)	2005-04-28
MA25832A1 (fr)	2003-07-01
EP1305311B1 (fr)	2008-01-16
DE60132461T2 (de)	2008-12-24
AU2001276506A1 (en)	2002-02-18
CA2417827A1 (fr)	2002-02-14
PL360662A1 (en)	2004-09-20
HUP0300778A2 (hu)	2003-11-28
HRP20030068B1 (en)	2008-07-31
PT1305311E (pt)	2008-04-07
DK1305311T3 (da)	2008-05-19
CN1455778A (zh)	2003-11-12
EA200300230A1 (ru)	2003-06-26
IL154275A (en)	2009-02-11
WO2002012232A1 (fr)	2002-02-14
GB0019224D0 (en)	2000-09-27
DE60132461D1 (de)	2008-03-06
SK1462003A3 (en)	2004-06-08
IL154275A0 (en)	2003-09-17
BG107604A (bg)	2003-09-30
ZA200300961B (en)	2004-04-01
HK1057358A1 (en)	2004-04-02
AP1785A (en)	2007-10-04
CY1107252T1 (el)	2012-11-21
ATE384059T1 (de)	2008-02-15
BR0112982A (pt)	2003-08-26
KR20030022355A (ko)	2003-03-15
SI1305311T1 (sl)	2008-04-30
AP2003002736A0 (en)	2003-03-31
JP2004505970A (ja)	2004-02-26
UA76720C2 (uk)	2006-09-15
NO324596B1 (no)	2007-11-26
ECSP034467A (es)	2003-03-31

Publication	Publication Date	Title
US20040048899A1 (en)	2004-03-11	Tartrate salts of thiazollidnedione derivative
US20060040993A1 (en)	2006-02-23	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Mesylate salt
EP1305311B1 (fr)	2008-01-16	Tartrate de derive de thiazolidinedione
OA12355A (en)	2004-03-19	Tartrate salts of thiazolidinedione derivative.
US20070185167A1 (en)	2007-08-09	Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
WO2003050113A1 (fr)	2003-06-19	Sel d'hydrogene sulfate de 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
OA12284A (en)	2003-11-10	Thiazolidinedione salt for treatment of diabetes mellitus.
US20040102485A1 (en)	2004-05-27	Tartrate salt of thiazolidinedione derivative
US20040038968A1 (en)	2004-02-26	Thiazolidinedione derivative and its use as antidiabetic
AU2001292028A1 (en)	2002-06-20	Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
WO2003050112A1 (fr)	2003-06-19	Hydrates de toluenesulfonate d'un derive de thiazolidinedione
NZ524029A (en)	2004-07-30	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine2,4-dione, L(+) tartrate salt or a solvate thereof
WO2003053964A1 (fr)	2003-07-03	Sel de 2-naphtalenesulfonate 5-(4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2, 4-dione et son utilisation contre le diabete sucre
WO2003050111A1 (fr)	2003-06-19	Sels de type toluenesulfonate issus d'un derive de la thiazolidinedione
WO2003050114A1 (fr)	2003-06-19	Sel de sulfate d'un derive de thiazolidinedione
HK1057358B (en)	2008-05-30	Tartrate salt of thiazolidinedione derivative